✦ LIBER ✦

PDB29 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENS UNDERGOING DIABETIC END-STAGE RENAL DISEASE

✍ Scribed by A Citarella; LG Mantovani; S Cammarota; E Menditto; S Riegler; S De Portu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB56 PHARMACOECONOMIC CONSEQUENCES OF L

✍ A Citarella; S de Portu; S Cammarota; E Menditto; LG Mantovani 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

PUK8 COST EFFECTIVENESS OF ICODEXTRINE-B

✍ F Garcia-Contreras; P Constantino-Casas; I Prieto-Arenas; D Amato; JC Blackburn; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Frequency and therapy of end-stage renal

✍ Zander, Eckhard; Schulz, Bernd; Jutzi, Erich; Templin, Rüdiger; Zenker, Klaus; S 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 384 KB

Effects of Losartan-based therapy on the

✍ Jiten Vora; George Carides; Paul Robinson 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 565 KB

We-P11:20 Impact of aortic valve calcifi

✍ Sato, A.; Nakagami, T.; Babazono, T.; Iwamoto, Y. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Successful treatment of bortezomib-refra

✍ Noriaki Kawano, Naoko Yokota-Ikeda, Kunihiro Minoda, Hiroshi Hashiguchi… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 386 KB